Page last updated: 2024-08-24

triazoles and Basal Ganglia Diseases

triazoles has been researched along with Basal Ganglia Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aguirre, C; Albeniz, JM; Echaburu, SD; García, MG; Hernandez, R; Lertxundi, U; Ruiz, B	1
Bedard, PJ; Belanger, N; Dare, A; Di Paolo, T; Gregoire, L; Grzelak, ME; Hadjtahar, A; Hodgson, RA; Hunter, JC; Kazdoba, TM; Neustadt, BR; Pond, AJ; Stamford, AW; Varty, GB	1
Berk, M; Wynchank, D	1

Trials

1 trial(s) available for triazoles and Basal Ganglia Diseases

Article	Year
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial. Human psychopharmacology, 2003, Volume: 18, Issue:4 Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Piperazines; Receptors, Serotonin, 5-HT2; Schizophrenia; Serotonin Antagonists; Substance-Related Disorders; Triazoles	2003

Article

Year

Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.

Human psychopharmacology, 2003, Volume: 18, Issue:4

Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Piperazines; Receptors, Serotonin, 5-HT2; Schizophrenia; Serotonin Antagonists; Substance-Related Disorders; Triazoles

2003

Other Studies

2 other study(ies) available for triazoles and Basal Ganglia Diseases

Article	Year
Possible interaction between letrozole and long-acting injectable zuclopenthixol. Nordic journal of psychiatry, 2015, Volume: 69, Issue:1 Topics: Aged; Antineoplastic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Dibenzothiazepines; Drug Interactions; Female; Humans; Letrozole; Nitriles; Quetiapine Fumarate; Schizophrenia; Triazoles	2015
Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Experimental neurology, 2010, Volume: 225, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Area Under Curve; Basal Ganglia; Basal Ganglia Diseases; Cebus; Disease Models, Animal; Female; Macaca fascicularis; Male; Motor Activity; Pyrimidines; Receptor, Adenosine A2A; Triazoles	2010

Article

Year

Possible interaction between letrozole and long-acting injectable zuclopenthixol.

Nordic journal of psychiatry, 2015, Volume: 69, Issue:1

Topics: Aged; Antineoplastic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Dibenzothiazepines; Drug Interactions; Female; Humans; Letrozole; Nitriles; Quetiapine Fumarate; Schizophrenia; Triazoles

2015

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.

Experimental neurology, 2010, Volume: 225, Issue:2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Area Under Curve; Basal Ganglia; Basal Ganglia Diseases; Cebus; Disease Models, Animal; Female; Macaca fascicularis; Male; Motor Activity; Pyrimidines; Receptor, Adenosine A2A; Triazoles

2010